9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

Vurolenatide 50 mg every two weeks (Q2W) dosing arm demonstrated a 30% reduction over six weeks in the primary endpoint of the Phase 2 study, mean reduction in total stool output (TSO), compared with a 32% increase for placebo - for a mean relative redu